Generic Augmentin price refers to the cost of generic amoxicillin and clavulanate potassium products corresponding to appropriate FDA-approved combination-antibiotic formulations. The generic medicine contains two active ingredients: amoxicillin, a penicillin-class antibacterial, and clavulanate, a beta-lactamase inhibitor. In the United States, generic amoxicillin/clavulanate is available in different immediate-release tablet strengths, chewable formulations and oral suspension concentrations. Because each product contains specific amounts of both components, comparing costs requires the complete strength pair, dosage form and prescription quantity rather than the abbreviated name amoxicillin or generic Augmentin.
Generic amoxicillin/clavulanate costs can vary across manufacturers, pharmacy supply arrangements, prescribed quantities and payment methods. FDA Orange Book records identify multiple approved generic applications for conventional 250 mg/125 mg, 500 mg/125 mg and 875 mg/125 mg tablets. However, an approved application does not establish current commercial distribution, local inventory or a particular retail price. Pharmacy listings may also use different manufacturer or labeler names for products associated with separate packaging and distribution arrangements. A useful generic cost comparison therefore distinguishes the approved product from the actual item a pharmacy proposes to dispense.
For patients reviewing an existing prescription, the practical task is to compare quotations for the same generic combination, strength, dosage form and quantity under clearly identified cash, discount or insurance terms. This guide explains the factors that influence generic pricing without publishing potentially outdated retailer offers or dollar amounts. It does not recommend changing antibiotic strengths or manufacturers for clinical reasons. Original branded prices belong in the brand Augmentin price guide, while the Augmentin suspension pricing guide covers liquid-specific cost comparisons.
The price of generic amoxicillin/clavulanate depends on the actual prescription product, its dosage form and strength, the quantity dispensed and the pharmacy's payment arrangements. A conventional 875 mg/125 mg tablet, a 500 mg/125 mg tablet and an oral suspension are different products for pricing purposes. A quotation that identifies only generic Augmentin does not contain enough information for a reliable comparison.
Generic medicines are generally approved through Abbreviated New Drug Applications, or ANDAs, when they meet applicable FDA requirements. Several companies may hold approvals for corresponding amoxicillin/clavulanate formulations. Their products can move through different distribution channels, and the dispensing pharmacy may purchase or obtain them under different commercial arrangements. These circumstances can contribute to price differences without establishing that one approved generic is clinically superior.
The generic manufacturer or labeler shown on a package is not necessarily the same entity as the ANDA holder. Distributors and repackagers may also be involved in the supply chain. A product's National Drug Code helps identify the actual listed package, but it does not independently establish FDA approval, therapeutic equivalence or current availability.
Pricing also depends on whether the patient is paying cash, using a prescription discount or applying insurance benefits. The amount displayed in a coupon search result may be an estimate subject to pharmacy participation and program terms. It should not be represented as a universal nationwide generic price.
The amoxicillin/clavulanate product guide explains the underlying combination medicine. This page concentrates on generic cost factors and pharmacy quotation methods rather than product selection or individualized prescribing.
Conventional immediate-release generic amoxicillin/clavulanate tablets are approved in strength pairs corresponding to 250 mg/125 mg, 500 mg/125 mg and 875 mg/125 mg. The first amount identifies amoxicillin and the second identifies clavulanic acid. These products must be distinguished from plain amoxicillin tablets, which contain no clavulanate.
FDA Orange Book records identify multiple generic applicants and approved products across these conventional tablet strengths. The existence of multiple ANDAs means that pharmacies may encounter different approved generic products, package identifiers and commercial suppliers. It does not establish which manufacturer is currently stocked by a particular pharmacy.
When comparing quotations, the prescribed strength and tablet count should remain fixed. A price for 20 tablets of one strength is not directly comparable to a different strength or quantity. The tablet strength also cannot be changed merely because another generic product appears less expensive.
The FDA specifically warns against substituting two conventional 250 mg/125 mg tablets for one 500 mg/125 mg tablet. Both options would contain 500 mg of amoxicillin in total, but the two lower-strength tablets would contain twice as much clavulanic acid. This illustrates why cost-saving calculations based only on amoxicillin milligrams are inappropriate.
Generic product appearance and packaging may vary by approved manufacturer or labeler. The pharmacy should verify that the medicine dispensed matches the complete prescription rather than relying on a familiar tablet color or a shortened product description.
The Augmentin tablets guide introduces the conventional tablet family. Detailed strength identification is available for 250/125 mg, 500/125 mg and 875/125 mg.
| Generic tablet strength | Amoxicillin per tablet | Clavulanic acid per tablet | Cost-comparison requirement |
|---|---|---|---|
| 250 mg/125 mg | 250 mg | 125 mg | Compare the same conventional immediate-release strength and prescribed tablet quantity. |
| 500 mg/125 mg | 500 mg | 125 mg | Confirm manufacturer or labeler, exact quantity and payment method. |
| 875 mg/125 mg | 875 mg | 125 mg | Verify the same product strength, quantity and pharmacy quotation conditions. |
Prescription quantity is one of the most important variables in a generic amoxicillin/clavulanate cost comparison. A pharmacy quotation normally applies to a specified number of tablets, not to the generic ingredient name in isolation. Two prices cannot be evaluated meaningfully if one refers to a different tablet count.
The total prescription charge may reflect the pharmacy's acquisition costs, dispensing arrangements, package availability and applicable payment contracts. As a result, the charge for a larger quantity should not be assumed to increase in an exactly proportional way. A simple price-per-tablet calculation can describe a quotation mathematically, but it does not establish the appropriate prescription quantity.
Original manufacturer packages and pharmacy-dispensed quantities are also different concepts. A drug may be marketed in manufacturer packages containing a particular number of tablets while a pharmacist dispenses the quantity authorized by an individual prescription under applicable rules. The original package size should not be confused with a recommended treatment duration.
Some online price-search tools default to a commonly used quantity or strength. That default may not match the patient's prescription. The quoted amount can therefore appear inconsistent with another source even when both refer to genuine generic amoxicillin/clavulanate products.
A reliable comparison holds the strength, dosage form, prescribed quantity, payment method and pharmacy location constant wherever possible. Patients should not request extra tablets or change the prescribed regimen to obtain a different unit price. Appropriate treatment quantity remains a clinical decision.
Multiple companies appear in U.S. FDA approval and drug-labeling records for amoxicillin/clavulanate products. The Orange Book identifies ANDA applicants and approved product entries, while DailyMed labeling can identify the labeler, distributor, packager and other product-specific details. These records help determine whether two pharmacy quotations concern the same type of approved generic medicine.
The 2026 FDA Orange Book includes conventional combination-tablet approval records associated with companies such as Aurobindo Pharma, Sandoz, Teva, Hikma and Micro Labs. The specific applications and approved strengths differ among applicants. A manufacturer's presence in the FDA directory should not be interpreted as evidence that every pharmacy carries all its products.
The distinction between an ANDA holder and a package labeler is important. A company may distribute or repackage an approved generic under a different NDC without becoming the original application holder. A quotation listing a different labeler name therefore does not automatically indicate a different underlying active-ingredient formulation.
Approved generic products may have different appearances, tablet markings, inactive ingredients and packaging within applicable regulatory requirements. These distinctions can matter during product identification, but price differences should not be used as evidence that a more expensive approved generic is necessarily more effective.
When manufacturer identity matters, the pharmacy can clarify the exact dispensed product and relevant identifiers. The FDA Orange Book is the appropriate reference for application and therapeutic-equivalence information; DailyMed can provide additional labeling details. Neither source is a live retailer pricing database.
The amoxicillin/clavulanate generic manufacturers directory explains ANDA holders, labelers and package records in detail. This cost guide addresses how those identities affect the interpretation of pharmacy quotations.
| Product identifier | Regulatory or labeling function | Relevance to pricing |
|---|---|---|
| ANDA number | Identifies an FDA-approved generic application. | Helps distinguish approved product families without establishing a retail price. |
| ANDA holder | Identifies the applicant responsible for the approved generic application. | May differ from the company named on the dispensed package. |
| Manufacturer | Identifies the company or establishment documented in a manufacturing role. | Can be relevant to sourcing but does not establish a national selling price. |
| Labeler or repackager | Identifies the entity associated with published product or package labeling. | Explains why different names or NDCs may appear in pharmacy listings. |
| NDC | Identifies a listed drug product or package. | Supports identification of the quoted product but does not prove stock or FDA approval. |
Generic amoxicillin/clavulanate oral suspensions are supplied as powder for reconstitution and identified by the amounts of both active ingredients per 5 mL of prepared liquid. Standard FDA-labeled concentration pairs include 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per 5 mL.
A meaningful liquid quotation identifies the complete concentration pair and final prepared bottle volume. A 75 mL bottle of one concentration is not equivalent to a 75 mL bottle of another concentration. The different products can contain different total amounts and proportions of amoxicillin and clavulanate.
Generic suspension pricing may vary by applicant, labeler, package configuration, pharmacy and payment method. FDA approval records describe the regulatory products, while DailyMed can provide package information. Neither resource establishes current commercial stock or a live transaction price.
The pharmacy must also confirm the preparation and dispensing requirements for the prescribed liquid. Standard oral suspensions require correct reconstitution and specified storage after preparation. These considerations distinguish liquid products from conventional tablets but do not justify changing concentrations independently.
Augmentin ES-600 is a separately labeled pediatric suspension containing 600 mg/42.9 mg per 5 mL after reconstitution. Its component ratio and substitution restrictions differ from the standard suspension family. It should not be included in ordinary generic-liquid comparisons without establishing the exact regulatory product relationship.
The Augmentin suspension price guide owns the detailed liquid-specific cost discussion. Product concentration, preparation and storage information belongs in the standard oral suspension guide, while Augmentin ES-600 covers the distinct pediatric formulation.
| Standard suspension strength | Amoxicillin-to-clavulanate ratio | Required quotation details |
|---|---|---|
| 125 mg/31.25 mg per 5 mL | 4:1 | Exact generic product, final bottle volume and payment method. |
| 200 mg/28.5 mg per 5 mL | Approximately 7:1 | Concentration, manufacturer or labeler, volume and pharmacy. |
| 250 mg/62.5 mg per 5 mL | 4:1 | Concentration, prepared volume and product identity. |
| 400 mg/57 mg per 5 mL | Approximately 7:1 | Exact concentration, final volume and quotation conditions. |
Original branded Augmentin and approved generic amoxicillin/clavulanate belong to related but distinct commercial pricing categories. The brand uses the proprietary Augmentin name, while generic products are marketed under the established ingredient names. A pharmacy may display both types of products under a single familiar search term.
Generic competition can affect purchasing and retail pricing arrangements, but the precise difference between brand and generic costs depends on the product, pharmacy, quantity and payment conditions. It is not appropriate to assign a universal discount percentage or claim that a particular generic is always the least expensive option without comparable current quotations.
An appropriately approved generic must satisfy applicable FDA requirements for its reference product, including relevant pharmaceutical-equivalence and bioequivalence standards. Such approval does not make every amoxicillin/clavulanate formulation interchangeable. Dosage form, strength and release characteristics remain essential.
Brand-specific availability is another consideration. A pharmacy may regularly dispense generic combination tablets while needing separate confirmation to supply the original branded product. A price-search heading that says Augmentin should therefore not be interpreted as proof that the displayed amount applies to brand-name medication.
If a prescription permits generic dispensing under applicable rules, the pharmacist can explain which approved product is being supplied. Patients should not change strength or dosage form based solely on a difference in displayed prices.
The brand Augmentin cost guide owns branded pricing factors. The Augmentin vs generic comparison addresses regulatory and product differences beyond price.
A generic cash price is a pharmacy quotation under a specified cash-payment arrangement. A coupon or prescription discount-card amount may be calculated under different agreements and eligibility conditions. These figures should not be combined into a single comparison without identifying how each amount was obtained.
Generic prescription discount services frequently display a default strength and tablet count. If those settings differ from the actual prescription, the advertised amount may not apply. The exact amoxicillin/clavulanate strength, dosage form and quantity should be confirmed before comparing an estimate with another pharmacy quotation.
Discount programs may also limit participation to certain pharmacies, products or quantities. Promotional first-use discounts can differ from ordinary recurring pricing. A low headline amount therefore does not establish that every patient can obtain the medicine under the same terms.
A pharmacy may quote a generic product from a different manufacturer or labeler than the item displayed in a search result. That difference requires product verification, especially if the product's dosage form, strength or inactive ingredients matter. It does not automatically indicate that either product is inappropriate.
Cash and coupon comparisons should preserve the quote date and pharmacy location because prices and program arrangements can change. This evergreen guide explains the comparison process without presenting retailer offers that may become outdated.
An insured patient's final cost for generic amoxicillin/clavulanate depends on the applicable plan and benefit terms. A generic medicine may be placed on a different formulary tier from the original brand, but actual copays, coinsurance and deductible-stage payments vary by plan. There is no single out-of-pocket amount that applies to all insured patients.
A formulary may identify covered products using the established ingredient name rather than Augmentin. Coverage can also depend on the exact strength, dosage form and pharmacy network. Consequently, a plan's treatment of conventional generic tablets should not automatically be assumed to apply to every liquid, chewable or extended-release combination product.
Copays are generally fixed patient cost-sharing amounts under the relevant benefit rules, while coinsurance is typically calculated as a percentage of an eligible cost. Deductibles and pharmacy-network conditions can affect the amount charged. The patient's final payment should be established through the pharmacy and insurer rather than inferred from a general generic-drug listing.
Prescription discount cards generally operate as an alternative payment arrangement rather than an additional insurance benefit for the same transaction. Patients should verify which terms apply and whether an advertised discount concerns the prescribed generic combination product.
The Augmentin insurance coverage guide addresses plan and formulary questions in greater detail. This page maintains its focus on generic cost comparisons instead of reproducing a complete insurance guide.
A reliable comparison begins with an existing valid prescription. The patient should identify the complete generic medicine, dosage form, strength pair and prescribed quantity. A price for plain amoxicillin, a different combination strength or an extended-release product is not a substitute for the intended conventional generic prescription.
The next step is to identify the actual product quoted by the pharmacy. The manufacturer or labeler and relevant NDC can help distinguish the dispensed product from a broad online listing. If a pharmacy proposes a different generic or formulation, the pharmacist must evaluate applicable FDA approval and prescription requirements.
Each quotation should retain the pharmacy name, U.S. location, date and payment method. Cash, discount-card and insurance amounts may differ for the same prescription. Comparisons should hold the strength, dosage form and quantity constant wherever possible rather than treating every search result for generic Augmentin as equivalent.
Availability must be confirmed separately. A product may have an FDA-approved ANDA and a published NDC without being stocked at a particular pharmacy. A quoted amount is not a guarantee that the medicine can be dispensed immediately.
If the exact prescribed product cannot be supplied, patients should seek professional guidance rather than changing antibiotic strength, combining tablets or substituting an oral suspension independently. The goal is to compare payment options for the correct prescription, not to select a different treatment on the basis of price.
The following checklist can be used for conventional tablets and, with concentration and bottle-volume details, standard oral suspensions.
| Quotation field | Information to verify | Purpose |
|---|---|---|
| Medicine | Amoxicillin and clavulanate potassium | Distinguishes the combination from plain amoxicillin. |
| Product type | FDA-approved generic combination product | Prevents confusion with original brand pricing. |
| Dosage form | Conventional tablet, chewable tablet or standard oral suspension | Keeps the quotation aligned with the prescription. |
| Strength | Complete two-component strength pair | Avoids comparisons between different formulations. |
| Quantity | Tablet count or final liquid volume | Allows like-for-like comparison. |
| Manufacturer or labeler | Actual company associated with the dispensed product | Helps reconcile different generic listings. |
| NDC | Relevant listed product or package identifier | Supports product identification. |
| Pharmacy and region | Pharmacy name and U.S. location | Preserves local pricing context. |
| Payment and date | Cash, discount or insurance terms and quotation date | Distinguishes current comparable offers from historical estimates. |
| Supply confirmation | Whether the pharmacy can dispense the prescribed product | Separates a price quotation from actual inventory. |
Generic amoxicillin/clavulanate remains a prescription-only antibacterial medicine in the United States. A lower price does not establish that the combination is appropriate for a particular infection or patient. The prescribing clinician must determine whether antibacterial treatment is indicated and which product is suitable.
The FDA distinguishes conventional immediate-release tablets, chewable formulations and standard oral suspensions. It also identifies Augmentin XR as a separate extended-release product and Augmentin ES-600 as a specialized pediatric liquid. These products cannot be treated as universally interchangeable merely because they share active ingredients.
An immediate-release generic tablet should not be assumed equivalent to Augmentin XR. Extended-release formulations have different release characteristics, while ES-600 has a different amoxicillin-to-clavulanate ratio from standard suspensions. Any proposed replacement requires an appropriate professional review of the exact approved product and prescription.
Safety considerations include serious penicillin-class hypersensitivity reactions, previous Augmentin-associated liver dysfunction, gastrointestinal adverse reactions and other warnings in applicable labeling. Patients should provide relevant allergy and medication information to their prescriber and pharmacist. A generic product's lower cost does not eliminate these risks.
Antibiotics do not treat viral illnesses such as influenza or the common cold. Patients should not share prescriptions, reuse leftover antibiotics, change tablet quantities or switch liquid concentrations to reduce expense. Such practices can create medication errors and contribute to inappropriate antibiotic use.
The Augmentin XR guide, ES-600 guide and penicillin allergy guide provide additional formulation and safety context. This page remains a generic pricing resource rather than a treatment-selection guide.
Generic amoxicillin/clavulanate does not have one universal U.S. retail price. Cost depends on the exact dosage form, two-component strength, quantity, pharmacy, location and payment method. A current pharmacy quotation is necessary to establish the applicable amount.
Pricing factors include the 875 mg/125 mg immediate-release tablet strength, prescribed quantity, actual generic product, pharmacy supply arrangements and cash, discount or insurance terms. A quotation for a different strength or dosage form should not be treated as equivalent.
Not necessarily. These are different prescription strengths, and pharmacy prices can vary by product, quantity and payment terms. Comparable quotations are needed to establish any price difference. Patients should not switch strengths independently to reduce cost.
Yes. FDA approval records include conventional immediate-release 250 mg/125 mg generic tablets. This strength contains 250 mg of amoxicillin and 125 mg of clavulanic acid per tablet and must be distinguished from the 250 mg/62.5 mg chewable formulation.
Quotations may differ because of product sourcing, available manufacturers, distribution arrangements, prescribed quantity, pharmacy location and payment contracts. A price shown by one pharmacy is not necessarily representative of another.
Different approved manufacturers or labelers may participate in different distribution and purchasing arrangements, which can affect pharmacy quotations. Manufacturer identity alone does not establish a universal retail price or imply that a more expensive approved generic is clinically superior.
No direct substitution should be made. Two 250/125 mg tablets contain a combined 500 mg of amoxicillin but 250 mg of clavulanic acid, while one 500/125 mg tablet contains only 125 mg of clavulanic acid. FDA labeling specifically identifies this substitution as inappropriate.
Yes. The quantity prescribed and dispensed can influence the total pharmacy charge. However, a larger quantity should not be assumed to produce a proportional price change or represent an appropriate prescription. Quantity must remain consistent with the clinician's instructions.
No universal price relationship can be guaranteed without comparable quotations. Generic and branded products may have different pricing, inventory and payment arrangements. The products must also be compared using the correct strength, dosage form and quantity.
Coupon estimates can vary by pharmacy, location, strength, quantity, discount program and promotional conditions. A displayed default quantity or strength may not match the actual prescription. The final terms should be confirmed with the dispensing pharmacy.
Some discount programs may offer eligible pricing for generic amoxicillin/clavulanate, but actual terms depend on the pharmacy, product, quantity and program. A displayed discount is not a guarantee of availability or a universal price.
Coverage depends on the insurance plan, formulary, pharmacy network and applicable benefit requirements. Generic tablets and other dosage forms may have different coverage conditions. A pharmacy or insurer must confirm the patient's actual cost.
Prescription discount cards generally operate as an alternative to insurance payment for a particular transaction rather than as an additional insurance benefit. Program terms vary, so the pharmacy should verify which payment method applies.
Liquid quotations depend on the complete concentration pair, final prepared bottle volume, approved product, pharmacy and payment method. A price for one concentration or volume cannot be assumed to apply to another.
No. Generic Augmentin refers to amoxicillin combined with clavulanate potassium. Plain amoxicillin contains only amoxicillin. They are different prescription medicines and should not be exchanged simply because one is less expensive.
No. Augmentin XR uses an extended-release formulation with a distinct strength pair and release profile. Conventional immediate-release generic combination tablets are not automatically interchangeable with XR.
Verify the complete two-component strength, dosage form, prescribed quantity, actual generic product, pharmacy location, payment method and quotation date. Ask whether the pharmacy can dispense the specified medicine and whether any proposed substitution is appropriate.
No. Generic amoxicillin/clavulanate is a prescription-only antibacterial medicine. Lawful dispensing requires a valid prescription and applicable pharmacy requirements. Low advertised prices do not establish prescription-free access.